Cargando…

Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples

The cardioprotective and anti-inflammatory effects of long chain omega-3 polyunsaturated fatty acids (n3 PUFA) are believed to be partly mediated by their oxygenated metabolites (oxylipins). In the last two decades interest in a novel group of autacoids termed specialized pro-resolving mediators (SP...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutzner, Laura, Rund, Katharina M., Ostermann, Annika I., Hartung, Nicole M., Galano, Jean-Marie, Balas, Laurence, Durand, Thierry, Balzer, Michael S., David, Sascha, Schebb, Nils Helge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416208/
https://www.ncbi.nlm.nih.gov/pubmed/30899221
http://dx.doi.org/10.3389/fphar.2019.00169
_version_ 1783403306813489152
author Kutzner, Laura
Rund, Katharina M.
Ostermann, Annika I.
Hartung, Nicole M.
Galano, Jean-Marie
Balas, Laurence
Durand, Thierry
Balzer, Michael S.
David, Sascha
Schebb, Nils Helge
author_facet Kutzner, Laura
Rund, Katharina M.
Ostermann, Annika I.
Hartung, Nicole M.
Galano, Jean-Marie
Balas, Laurence
Durand, Thierry
Balzer, Michael S.
David, Sascha
Schebb, Nils Helge
author_sort Kutzner, Laura
collection PubMed
description The cardioprotective and anti-inflammatory effects of long chain omega-3 polyunsaturated fatty acids (n3 PUFA) are believed to be partly mediated by their oxygenated metabolites (oxylipins). In the last two decades interest in a novel group of autacoids termed specialized pro-resolving mediators (SPMs) increased. These are actively involved in the resolution of inflammation. SPMs are multiple hydroxylated fatty acids including resolvins, maresins, and protectins derived from the n3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as lipoxins derived from arachidonic acid (ARA). In the present paper, we developed an LC-MS/MS method for a comprehensive set of 18 SPMs derived from ARA, EPA, and DHA and integrated it into our targeted metabolomics platform. Quantification was based on external calibration utilizing five deuterated internal standards in combination with a second internal standard for quality assessment of sample preparation in each sample. The tandem mass spectrometric parameters were carefully optimized for sensitive and specific detection. The influence of source parameters of the used AB Sciex 6500 QTRAP instrument as well as electronic parameters and the selection of transitions are discussed. The method was validated/characterized based on the criteria listed in the European Medicines Agency (EMA) guideline on bioanalytical method validation and method performance is demonstrated regarding recovery of internal standards (between 78 ± 4% and 87 ± 3% from 500 μL of human serum) as well as extraction efficacy of SPMs in spiked plasma (intra-day accuracy within ±20 and ±15% at 0.1 and 0.3 nM in plasma, respectively). Based on the lower limit of quantification of 0.02–0.2 nM, corresponding to 0.18–2.7 pg on column, SPMs were generally not detectable/quantifiable in plasma and serum supporting that circulating levels of SPMs are very low, i.e., <0.1 nM in healthy subjects. Following septic shock or peritonitis, SPMs could be quantified in the samples of several patients. However, in these studies with a small number of patients no clear correlation with severity of inflammation could be observed.
format Online
Article
Text
id pubmed-6416208
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64162082019-03-21 Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples Kutzner, Laura Rund, Katharina M. Ostermann, Annika I. Hartung, Nicole M. Galano, Jean-Marie Balas, Laurence Durand, Thierry Balzer, Michael S. David, Sascha Schebb, Nils Helge Front Pharmacol Pharmacology The cardioprotective and anti-inflammatory effects of long chain omega-3 polyunsaturated fatty acids (n3 PUFA) are believed to be partly mediated by their oxygenated metabolites (oxylipins). In the last two decades interest in a novel group of autacoids termed specialized pro-resolving mediators (SPMs) increased. These are actively involved in the resolution of inflammation. SPMs are multiple hydroxylated fatty acids including resolvins, maresins, and protectins derived from the n3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as lipoxins derived from arachidonic acid (ARA). In the present paper, we developed an LC-MS/MS method for a comprehensive set of 18 SPMs derived from ARA, EPA, and DHA and integrated it into our targeted metabolomics platform. Quantification was based on external calibration utilizing five deuterated internal standards in combination with a second internal standard for quality assessment of sample preparation in each sample. The tandem mass spectrometric parameters were carefully optimized for sensitive and specific detection. The influence of source parameters of the used AB Sciex 6500 QTRAP instrument as well as electronic parameters and the selection of transitions are discussed. The method was validated/characterized based on the criteria listed in the European Medicines Agency (EMA) guideline on bioanalytical method validation and method performance is demonstrated regarding recovery of internal standards (between 78 ± 4% and 87 ± 3% from 500 μL of human serum) as well as extraction efficacy of SPMs in spiked plasma (intra-day accuracy within ±20 and ±15% at 0.1 and 0.3 nM in plasma, respectively). Based on the lower limit of quantification of 0.02–0.2 nM, corresponding to 0.18–2.7 pg on column, SPMs were generally not detectable/quantifiable in plasma and serum supporting that circulating levels of SPMs are very low, i.e., <0.1 nM in healthy subjects. Following septic shock or peritonitis, SPMs could be quantified in the samples of several patients. However, in these studies with a small number of patients no clear correlation with severity of inflammation could be observed. Frontiers Media S.A. 2019-03-07 /pmc/articles/PMC6416208/ /pubmed/30899221 http://dx.doi.org/10.3389/fphar.2019.00169 Text en Copyright © 2019 Kutzner, Rund, Ostermann, Hartung, Galano, Balas, Durand, Balzer, David and Schebb. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kutzner, Laura
Rund, Katharina M.
Ostermann, Annika I.
Hartung, Nicole M.
Galano, Jean-Marie
Balas, Laurence
Durand, Thierry
Balzer, Michael S.
David, Sascha
Schebb, Nils Helge
Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
title Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
title_full Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
title_fullStr Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
title_full_unstemmed Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
title_short Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
title_sort development of an optimized lc-ms method for the detection of specialized pro-resolving mediators in biological samples
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416208/
https://www.ncbi.nlm.nih.gov/pubmed/30899221
http://dx.doi.org/10.3389/fphar.2019.00169
work_keys_str_mv AT kutznerlaura developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT rundkatharinam developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT ostermannannikai developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT hartungnicolem developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT galanojeanmarie developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT balaslaurence developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT durandthierry developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT balzermichaels developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT davidsascha developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples
AT schebbnilshelge developmentofanoptimizedlcmsmethodforthedetectionofspecializedproresolvingmediatorsinbiologicalsamples